Centrexion Therapeutics is a biopharmaceutical product development company seeking to develop a new class of therapeutics that stops pain at its source. Its non-opioid clinical stage product candidates selectively deactivate pain fibers to provide patients with long lasting relief. Centrexion’s pipeline targets major unmet needs in the treatment of severe pain caused by human and canine osteoarthritis, nerve injury, and herpes zoster viral infection.